• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 4. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 5. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147

• Solvents and Organic Chemicals Organic Compounds Organohalogen compounds Aryl halides Aryl bromides

Comprehensive Overview of 2-(4-Bromothien-2-yl)-1,3-dioxolane (CAS No. 58267-85-9): Properties, Applications, and Industry Insights

2-(4-Bromothien-2-yl)-1,3-dioxolane (CAS No. 58267-85-9) is a specialized organic compound that has garnered significant attention in pharmaceutical and materials science research. This brominated heterocyclic derivative features a thiophene ring coupled with a 1,3-dioxolane protecting group, making it a versatile intermediate for synthetic chemistry. With growing interest in heterocyclic building blocks and halogenated compounds, this molecule addresses key demands in drug discovery and advanced material design.

The structural uniqueness of 2-(4-Bromothien-2-yl)-1,3-dioxolane lies in its balanced reactivity profile. The bromine substituent at the 4-position enables cross-coupling reactions (e.g., Suzuki-Miyaura or Buchwald-Hartwig), while the dioxolane group offers protection for carbonyl functionalities—a critical feature for multi-step syntheses. Recent publications highlight its utility in developing thiophene-based OLED materials and bioactive molecules, aligning with trends in green chemistry and sustainable synthesis.

Analytical characterization of CAS No. 58267-85-9 typically involves GC-MS, NMR (1H/13C), and HPLC purity testing. Researchers emphasize its stability under inert atmospheres, with optimal storage at 2-8°C. Industry benchmarks show ≥95% purity grades meeting requirements for high-throughput screening and preclinical studies, responding to the pharmaceutical sector's demand for reliable chemical intermediates.

Emerging applications leverage the compound's photophysical properties. Studies demonstrate its potential in designing organic semiconductors and non-linear optical materials, particularly for flexible electronics—a market projected to grow at 8.7% CAGR through 2030. The thiophene-dioxolane scaffold also shows promise in metal-organic frameworks (MOFs) for gas storage applications.

From a commercial perspective, 2-(4-Bromothien-2-yl)-1,3-dioxolane is available through specialty chemical suppliers with GMP-compliant documentation. Pricing trends reflect increased adoption, with bulk quantities (100g+) showing 12-15% year-over-year demand growth. Regulatory status varies by region, but current SDS data indicates standard handling protocols for laboratory chemicals under proper ventilation.

Ongoing research explores derivatization pathways, particularly for bioconjugation and polymeric materials. Patent analysis reveals 28 filings since 2020 incorporating this scaffold, primarily in antiviral agents and conductive polymers. These developments position CAS No. 58267-85-9 as a critical tool for innovators addressing challenges in personalized medicine and renewable energy technologies.

For synthetic chemists, protocol optimization studies suggest improved yields (up to 78%) via microwave-assisted synthesis techniques. The compound's compatibility with flow chemistry systems further enhances its appeal for industrial-scale production. Environmental impact assessments show favorable biodegradation potential compared to analogous halogenated compounds.

Academic and industrial collaborations are advancing novel formulations combining 2-(4-Bromothien-2-yl)-1,3-dioxolane with nanomaterials for sensor applications. Recent conferences have highlighted its role in developing COVID-19 therapeutic candidates through structure-activity relationship (SAR) studies, though clinical validation remains ongoing.

Quality control protocols for CAS No. 58267-85-9 emphasize residual solvent analysis, particularly for genotoxic impurity control. Leading suppliers now provide detailed spectral libraries and stability data packages, responding to stringent ICH guidelines in pharmaceutical applications.

Future directions may explore enzymatic resolution of stereoisomers and continuous manufacturing processes. As the chemical industry shifts toward digital transformation, computational models predicting the compound's behavior in catalytic systems are gaining traction—addressing key questions about selectivity and reaction kinetics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)